Zacks: Brokerages Expect Urovant Sciences Ltd (NASDAQ:UROV) Will Announce Earnings of -$0.96 Per Share

Wall Street analysts expect that Urovant Sciences Ltd (NASDAQ:UROV) will announce earnings of ($0.96) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Urovant Sciences’ earnings. The highest EPS estimate is ($0.86) and the lowest is ($1.08). Urovant Sciences posted earnings of ($0.87) per share in the same quarter last year, which suggests a negative year over year growth rate of 10.3%. The business is scheduled to announce its next earnings report on Wednesday, February 12th.

According to Zacks, analysts expect that Urovant Sciences will report full-year earnings of ($4.05) per share for the current fiscal year, with EPS estimates ranging from ($4.38) to ($3.63). For the next fiscal year, analysts anticipate that the firm will report earnings of ($4.27) per share, with EPS estimates ranging from ($5.39) to ($3.62). Zacks’ earnings per share averages are a mean average based on a survey of research analysts that follow Urovant Sciences.

Urovant Sciences (NASDAQ:UROV) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.30.

UROV has been the subject of a number of research reports. ValuEngine lowered shares of Urovant Sciences from a “hold” rating to a “sell” rating in a report on Monday, December 16th. HC Wainwright raised their price target on shares of Urovant Sciences from $28.00 to $33.00 and gave the company a “buy” rating in a report on Tuesday, December 31st. Finally, Zacks Investment Research lowered shares of Urovant Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, November 6th. Two investment analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. Urovant Sciences currently has an average rating of “Hold” and a consensus target price of $22.69.

Shares of Urovant Sciences stock opened at $14.39 on Friday. The company has a debt-to-equity ratio of 1.83, a current ratio of 6.65 and a quick ratio of 6.65. The firm has a market cap of $478.51 million, a P/E ratio of -3.25 and a beta of 1.97. The firm has a 50 day simple moving average of $12.84 and a 200 day simple moving average of $9.88. Urovant Sciences has a fifty-two week low of $6.45 and a fifty-two week high of $15.98.

Institutional investors have recently modified their holdings of the stock. Marshall Wace North America L.P. acquired a new stake in shares of Urovant Sciences in the first quarter valued at approximately $49,000. Northern Trust Corp increased its holdings in shares of Urovant Sciences by 55.8% in the second quarter. Northern Trust Corp now owns 17,164 shares of the company’s stock valued at $136,000 after purchasing an additional 6,144 shares in the last quarter. First Trust Advisors LP acquired a new stake in shares of Urovant Sciences in the third quarter valued at approximately $163,000. Marshall Wace LLP acquired a new stake in shares of Urovant Sciences in the first quarter valued at approximately $325,000. Finally, LVW Advisors LLC acquired a new stake in shares of Urovant Sciences in the third quarter valued at approximately $372,000. 22.37% of the stock is owned by institutional investors and hedge funds.

About Urovant Sciences

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.

Featured Story: What sectors are represented in the Nikkei Index?

Get a free copy of the Zacks research report on Urovant Sciences (UROV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Urovant Sciences (NASDAQ:UROV)

Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.